Literature DB >> 19935448

Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?

Natalia Jimenez-Truque1, Isaac Thomsen, Elizabeth Saye, C Buddy Creech.   

Abstract

Methicillin-resistant Staphylococcus aureus isolates with vancomycin minimal inhibitory concentrations (MICs) >or=1.5 microg/mL have been associated with poorer clinical outcomes and treatment failures in adults. We evaluated vancomycin MICs in 71 invasive pediatric community-acquired MRSA isolates from 2004 to 2008, using the E-test micromethod and the E-test macro-method. The modal MIC by micromethod was 1.5 microg/mL, and median vancomycin MICs did not increase over time.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19935448      PMCID： PMC3848324          DOI： 10.1097/INF.0b013e3181c52a04

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  15 in total

Review 1.  Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.

Authors:  Ronald N Jones
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

2.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

3.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

4.  Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.

Authors:  Guiqing Wang; Janet F Hindler; Kevin W Ward; David A Bruckner
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

5.  A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.

Authors:  Mandy Wootton; Alasdair P MacGowan; Timothy R Walsh; Robin A Howe
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

6.  Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.

Authors:  Donald I Hsu; Levita K Hidayat; Ryan Quist; Janet Hindler; Asa Karlsson; Anne Yusof; Annie Wong-Beringer
Journal:  Int J Antimicrob Agents       Date:  2008-08-12       Impact factor: 5.283

7.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

8.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

9.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

10.  Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.

Authors:  Juan-Ignacio Alós; Ana García-Cañas; Paloma García-Hierro; Francisco Rodríguez-Salvanés
Journal:  J Antimicrob Chemother       Date:  2008-06-13       Impact factor: 5.790
View more
  5 in total

1.  Pediatric pharmacokinetics of vancomycin: a canadian perspective.

Authors:  Anais Delicourt; Jean-François Bussières; Denis Lebel
Journal:  Can J Hosp Pharm       Date:  2011-03

2.  Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.

Authors:  Andrea Hahn; Robert W Frenck; Mary Allen-Staat; Yuanshu Zou; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2015-10       Impact factor: 3.681

3.  Validation of a pediatric population pharmacokinetic model for vancomycin.

Authors:  Andrea Hahn; Robert W Frenck; Yuanshu Zou; Alexander A Vinks
Journal:  Ther Drug Monit       Date:  2015-06       Impact factor: 3.681

4.  The effect of age and weight on vancomycin serum trough concentrations in pediatric patients.

Authors:  Theresa Madigan; Ronald M Sieve; Kevin K Graner; Ritu Banerjee
Journal:  Pharmacotherapy       Date:  2013-07-17       Impact factor: 4.705

5.  Effects of aggregate and individual antibiotic exposure on vancomycin MICs for Staphylococcus aureus isolates recovered from pediatric patients.

Authors:  Lucia Rose; Shannon Chan; Jobayer Hossain; M Cecilia Di Pentima
Journal:  J Clin Microbiol       Date:  2013-06-19       Impact factor: 5.948
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.